MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

ClinicalTrials.gov ID: NCT01748721

Public ClinicalTrials.gov record NCT01748721. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 12, 2026, 7:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors

Study identification

NCT ID: NCT01748721
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Morphotek; Industry
Enrollment: 27 participants

Conditions and interventions

Conditions

Interventions

anti-endosialin/TEM1 monoclonal antibody MORAb-004 Biological
laboratory biomarker analysis Other
pharmacological study Other

Biological · Other

Eligibility (public fields only)

Age range: 13 Months to 21 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 31, 2013
Primary completion: Apr 30, 2015
Completion: Apr 30, 2015
Last update posted: Jan 7, 2016

2013 – 2015

United States locations

U.S. sites: 20
U.S. states: 17
U.S. cities: 20

Facility	City	State	ZIP	Site status
Children's Hospital of Alabama	Birmingham	Alabama	35233	—
Children's Hospital of Orange County	Orange	California	92868	—
University of California San Francisco Medical Center - Parnassus	San Francisco	California	94143	—
Children's National Medical Center	Washington D.C.	District of Columbia	20310	—
Children's Healthcare of Atlanta-Egleston	Atlanta	Georgia	30307	—
Ann and Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois	18150	—
Riley Hospital for Children	Indianapolis	Indiana	46202	—
C S Mott Children's Hospital	Ann Arbor	Michigan	48109	—
University of Minnesota Cancer Center-Fairview	Minneapolis	Minnesota	55435	—
Washington University School of Medicine	St Louis	Missouri	63110	—
Columbia University Medical Center	New York	New York	10032	—
Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio	45229	—
Rainbow Babies & Children's Hospital	Cleveland	Ohio	44106	—
Oregon Health and Science University	Portland	Oregon	97239	—
Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	19104	—
Children's Hospital of Pittsburgh of UPMC	Pittsburgh	Pennsylvania	15224	—
Saint Jude Children's Research Hospital	Memphis	Tennessee	38105	—
Baylor College of Medicine	Houston	Texas	77030	—
Seattle Children's Hospital	Seattle	Washington	98105	—
Midwest Children's Cancer Center	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01748721, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 7, 2016 · Synced May 12, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01748721 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →